Psoriasis Drug MIA

Article

San Francisco - The anti-CD40 ligand monoclonal antibody IDEC-131, manufactured by IDEC Pharmaceuticals, was developed to treat autoimmune and inflammatory diseases, such as psoriasis. IDEC-131 targets the CD40 ligand on T cells and regulates the interaction between T cells and B cells.

Related Videos
Related Content

Discovering Dermatology Times: September 2023 BCC Management Supplement

September 29th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Incyte to Present Numerous Studies at EADV 2023

September 29th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Prolonged Remission in Rosacea: A Breakthrough With Subantibiotic Dose of Oral Doxycycline

September 29th 2023

Rocco Serrao, MD Looks Ahead to Bimekizumab’s Approval

September 29th 2023

Discovering Dermatology Times: September 2023 BCC Management Supplement

September 29th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Incyte to Present Numerous Studies at EADV 2023

September 29th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Prolonged Remission in Rosacea: A Breakthrough With Subantibiotic Dose of Oral Doxycycline

September 29th 2023

Rocco Serrao, MD Looks Ahead to Bimekizumab’s Approval

September 29th 2023

Discovering Dermatology Times: September 2023 BCC Management Supplement

September 29th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Incyte to Present Numerous Studies at EADV 2023

September 29th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Prolonged Remission in Rosacea: A Breakthrough With Subantibiotic Dose of Oral Doxycycline

September 29th 2023

Rocco Serrao, MD Looks Ahead to Bimekizumab’s Approval

September 29th 2023
© 2023 MJH Life Sciences

All rights reserved.